Published in Thromb Haemost on February 28, 1989
Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol (2009) 2.43
Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol (2009) 2.22
A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol (2011) 2.19
Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J (2010) 1.95
Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis (2008) 1.56
Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med (2008) 1.52
Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis (2008) 1.29
HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res (2008) 1.20
Serum and dietary magnesium and risk of ischemic stroke: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2009) 1.19
Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol (2009) 1.11
Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev (2011) 1.11
Hemostatic and inflammatory risk factors for intracerebral hemorrhage in a pooled cohort. Stroke (2008) 1.09
High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood (2008) 1.07
Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol (2010) 1.06
IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1beta and C-reactive protein. Hum Genet (2008) 1.06
Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol (2011) 1.03
Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost (2009) 0.99
Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost (2009) 0.96
Carotid artery wall thickness and risk of stroke subtypes: the atherosclerosis risk in communities study. Stroke (2010) 0.93
Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol (2015) 0.92
Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis (2012) 0.92
Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the atherosclerosis risk in communities (ARIC) cohort. Arterioscler Thromb Vasc Biol (2009) 0.92
Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis (2008) 0.91
The metabolic syndrome and cognitive decline in the Atherosclerosis Risk in Communities study (ARIC). Dement Geriatr Cogn Disord (2014) 0.88
Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2015) 0.86
Smoking, fibrinogen and cancer mortality. J Natl Med Assoc (2007) 0.86
Longer legs are associated with greater risk of incident venous thromboembolism independent of total body height. The Longitudinal Study of Thromboembolism Etiology (LITE). Thromb Haemost (2011) 0.84
The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study. Am J Epidemiol (2013) 0.83
Serum 25-hydroxyvitamin D, calcium, phosphorus, and electrocardiographic QT interval duration: findings from NHANES III and ARIC. J Clin Endocrinol Metab (2011) 0.81
Anemia and the onset of gout in a population-based cohort of adults: Atherosclerosis Risk in Communities study. Arthritis Res Ther (2012) 0.80
Association of White Blood Cell Count and Differential with the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One (2015) 0.80
Ankle-brachial index and physical function in older individuals: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis (2016) 0.77
Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging: Atherosclerosis Risk in Communities Study. Stroke (2015) 0.77
Assessment of coronary heart disease risk by combined analysis of coagulation factors. Atherosclerosis (2008) 0.75
Association of Single Nucleotide Polymorphisms in the ST3GAL4 Gene with VWF Antigen and Factor VIII Activity. PLoS One (2016) 0.75
Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study. Thromb Res (2016) 0.75
Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc (2017) 0.75
Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease: The Atherosclerosis Risk in Communities Study. Stroke (2017) 0.75
Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med (1993) 5.14
Poly(ethylenimine) and its role in gene delivery. J Control Release (1999) 3.78
Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation (1997) 3.27
Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost (1993) 3.12
Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S A (1999) 2.81
Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res (1999) 2.33
Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation (2001) 2.32
A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet (1974) 2.29
Detailed alignment of saccharum and sorghum chromosomes: comparative organization of closely related diploid and polyploid genomes. Genetics (1998) 2.24
Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation (1999) 2.08
Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol (2001) 1.73
Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials (2001) 1.65
Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A (1999) 1.60
Water immersion versus standard colonoscopy insertion technique: randomized trial shows promise for minimal sedation. Endoscopy (2010) 1.56
Poly(ethylenimine)-mediated transfection: a new paradigm for gene delivery. J Biomed Mater Res (2000) 1.50
Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation (1999) 1.49
Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura. Lancet (1981) 1.49
State of complementary and alternative medicine in cardiovascular, lung, and blood research: executive summary of a workshop. Circulation (2001) 1.47
Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun (1994) 1.44
Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis (1991) 1.40
Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency. Gene Ther (1999) 1.31
Stimulation of de novo synthesis of prostaglandin G/H synthase in human endothelial cells by phorbol ester. J Biol Chem (1988) 1.28
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res (2001) 1.25
Metastatic tumors of the hand: a report of six cases. J Hand Surg Am (1978) 1.24
Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res (1995) 1.20
Increased platelet aggregates in patients with transient ischemic attacks. Stroke (1975) 1.20
Recording and analyzing high-density event-related potentials with infants. Using the Geodesic sensor net. Dev Neuropsychol (2001) 1.20
Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care (1999) 1.16
Aspirin and salicylate: An old remedy with a new twist. Circulation (2000) 1.15
Fallibility of the clinical diagnosis of venous thrombosis. JAMA (1975) 1.14
Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J Biol Chem (2001) 1.12
Cysteine 99 of endothelial nitric oxide synthase (NOS-III) is critical for tetrahydrobiopterin-dependent NOS-III stability and activity. Biochem Biophys Res Commun (1995) 1.10
Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb (1993) 1.08
Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb (1993) 1.08
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications. Thromb Haemost (1976) 1.06
Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem (1994) 1.06
Smoking cessation among Hong Kong Chinese smokers attending hospital as outpatients: impact of doctors' advice, successful quitting and intention to quit. Asia Pac J Public Health (2004) 1.06
Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation (1995) 1.05
Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase. J Clin Invest (1988) 1.03
Metastatic tumors of the foot. South Med J (1978) 1.02
Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J Biol Chem (2000) 1.01
Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med (1978) 1.00
Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma /Janus kinase 2/MEK-1-dependent pathway. J Biol Chem (2001) 1.00
Endothelial nitric-oxide synthase. Evidence for bidomain structure and successful reconstitution of catalytic activity from two separate domains generated by a baculovirus expression system. J Biol Chem (1996) 1.00
Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost (1994) 0.98
Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem (1995) 0.97
Characterization of the roles of the 594-645 region in human endothelial nitric-oxide synthase in regulating calmodulin binding and electron transfer. J Biol Chem (2000) 0.96
Platelet Pl(A2) allele and incidence of coronary heart disease: results from the Atherosclerosis Risk In Communities (ARIC) Study. Circulation (2000) 0.96
Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet (1999) 0.96
Distributions of hemostatic variables in blacks and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) Study. Ethn Dis (1992) 0.96
Detection of deep vein thrombosis with an automatic electrically calibrated strain gauge plethysmograph. Surgery (1977) 0.95
Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem Biophys Res Commun (1993) 0.94
Molecular cloning and characterization of bovine prostacyclin synthase. Biochem Biophys Res Commun (1994) 0.94
Flow cytometric studies of platelet responses to shear stress in whole blood. Biorheology (1995) 0.94
Mutation of Glu-361 in human endothelial nitric-oxide synthase selectively abolishes L-arginine binding without perturbing the behavior of heme and other redox centers. J Biol Chem (1997) 0.93
Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost (1995) 0.93
A comparison of methods for the study of platelet hyperfunction in thromboembolic disorders. Br J Haematol (1980) 0.92
Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. FASEB J (2000) 0.91
Expression of prostaglandin H synthase (cyclooxygenase) in Hodgkin's mononuclear and Reed-Sternberg cells. Functional resemblance between H-RS cells and histiocytes or interdigitating reticulum cells. Am J Pathol (1988) 0.91
Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor delta activation: implication in IVF. Hum Reprod (2006) 0.91
Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler Thromb (1993) 0.90
Prostacyclin stabilising factor deficiency in thrombotic thrombocytopenic purpura. Lancet (1982) 0.90
Primary structure of human thromboxane synthase determined from the cDNA sequence. J Biol Chem (1992) 0.90
Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest (1995) 0.89
Extra-osseous chondrosarcoma. Report of five cases and review of the literature. J Bone Joint Surg Am (1980) 0.89
Transcriptional regulation of endothelial nitric-oxide synthase by lysophosphatidylcholine. J Biol Chem (1998) 0.89
Determinants of population changes in fibrinogen and factor VII over 6 years: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol (2000) 0.89
Cyclooxygenase-2 induction in congestive heart failure: friend or foe? Circulation (1998) 0.89
Plasma agouti-related protein level: a possible correlation with fasted and fed states in humans and rats. J Neuroendocrinol (2002) 0.89
Cloning and expression analysis of a novel salicylate suppressible gene, Hs-CUL-3, a member of cullin/Cdc53 family. J Biol Chem (1998) 0.89
COX-2 expression and cell cycle progression in human fibroblasts. Am J Physiol Cell Physiol (2001) 0.89
Prostacyclin synthase active sites. Identification by molecular modeling-guided site-directed mutagenesis. J Biol Chem (1997) 0.89
ARIC hemostasis study--III. Quality control. Atherosclerosis Risk in Communities. Thromb Haemost (1993) 0.89
Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation (1996) 0.88
Role of Sp1 in transcriptional activation of human nitric oxide synthase type III gene. Biochem Biophys Res Commun (1995) 0.88
Transcriptional regulation of endothelial nitric-oxide synthase by an interaction between casein kinase 2 and protein phosphatase 2A. J Biol Chem (1999) 0.88
Ultrasound in the diagnosis of posterior tibial tendon pathology. Foot Ankle Int (1996) 0.88
Primary malignant giant cell tumor of bone: "dedifferentiated" giant cell tumor. Mod Pathol (1989) 0.88
Letter: Gnidimacrin and gnidimacrin 20-palmitate, novel macrocyclic antileukemic diterpenoid esters from Gnidia subcordata1,2. J Am Chem Soc (1976) 0.88
Prospective study of the A455V polymorphism in the thrombomodulin gene, plasma thrombomodulin, and incidence of venous thromboembolism: the LITE Study. J Thromb Haemost (2003) 0.88
The Val192Leu mutation in the alpha-subunit of beta-hexosaminidase A is not associated with the B1-variant form of Tay-Sachs disease. Am J Hum Genet (1996) 0.87
Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens (1998) 0.87
Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study. Cerebrovasc Dis (2009) 0.87
Stimulation of endothelial cell prostacyclin formation by interleukin-2. Lymphokine Res (1986) 0.87
Shear stress differentially regulates PGHS-1 and PGHS-2 protein levels in human endothelial cells. Ann Biomed Eng (2000) 0.86
Interaction between lymphocytes and platelets in the synthesis of prostacyclin. J Clin Invest (1987) 0.86
Accuracy of Doppler ultrasound in clinically suspected venous thrombosis of the calf. Surg Gynecol Obstet (1976) 0.86
Association of hemostatic variables with MRI-detected cerebral abnormalities: the atherosclerosis risk in communities study. Neuroepidemiology (2001) 0.85
Differential effects of two doses of aspirin on platelets-vessel wall introduction in vivo. J Clin Invest (1981) 0.85
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem (2001) 0.85
Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis (2001) 0.85
Involvement of two Sp1 elements in basal endothelial prostaglandin H synthase-1 promoter activity. J Biol Chem (1997) 0.84
Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb (1993) 0.84
Abnormal platelet response to thromboxane A2. J Clin Invest (1981) 0.84
Characterization of the complete genomic structure of human thromboxane synthase gene and functional analysis of its promoter. Arch Biochem Biophys (1996) 0.84
Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis. Circulation (1976) 0.84
Differentiation-associated expression of prostaglandin H and thromboxane A synthases in monocytoid leukemia cell lines. Blood (1991) 0.84
Use of platelet aggregometry in selection of compatible platelet donors. N Engl J Med (1975) 0.84